Pharmaceutical companies lose between $200 billion and $400 billion in annual revenue to patent expirations between 2025 and 2030. This […]

The Statute That Rewired the Drug Industry In September 1984, President Reagan signed two pieces of legislation that had been

Branded Generics: The $400 Billion Business That Big Pharma Can’t Ignore In the summer of 2022, a pharmacist in Lagos

The companies winning enterprise contracts in biopharma data intelligence aren’t selling better patent databases. They’re selling a connected answer to

Every major drug patent expiration triggers a predictable downstream event: the originator company races to defend margin, and a dozen

The LOE Wave Nobody in Equipment Sales Is Talking About Between 2024 and 2029, roughly $130 billion worth of branded

The Revenue Cliff Is Real, and So Is Your Window Every year, billions of dollars in branded pharmaceutical revenue evaporate

The Geography Problem Nobody Warns You About The patent expired. You know the date, you have it in your spreadsheet,

The race for biosimilar first-mover advantage is decided long before the FDA approves a single molecule. It is decided in